ReviewCardiovascular drugs and therapy2022

Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.

Juan Antonio Requena-Ibáñez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.